FDA OKs Olaparib-Abiraterone for Metastatic Prostate Cancer

(MedPage Today) -- The FDA has approved the PARP inhibitor olaparib (Lynparza) in combination with abiraterone (Zytiga) for BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC), the agency announced Wednesday. Adult patients should...
Source: MedPage Today Public Health - Category: American Health Source Type: news